Aim Approximately 20% of patients treated with neoadjuvant chemoradiotherapy (nCRT) for
locally advanced rectal cancer achieve a pathological complete response (p CR) while the …

Simple Summary Identification of novel molecular markers of pathological complete
response (pCR) to preoperative radiation-based therapy in locally advanced rectal cancer …

While prognostic factors can help to classify the standard risk of subpopulations of patients
with the same tumor entity, it is still not possible to predict the response of individual patients …

Purpose To investigate the association between KRAS mutation and prognosis in rectal
cancer patients with neoadjuvant chemoradiotherapy. Methods Literature was searched in …

Colorectal cancer is one of the leading causes of cancer death worldwide. Over the last
decades, several studies have shown that tumor-related genomic alterations predict tumor …

INTRODUCTION: The current management of locally advanced rectal cancer involves total
mesorectal excision, which may be preceded by neo-adjuvant chemoradiotherapy (CRT) …

At this time, the use of oxaliplatin or targeted agents as component of multimodality
treatment for rectal cancer outside of a clinical trial is not recommended. The inclusion of …

Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard
treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3‐4, N0, M0) …

Epidermal growth factor receptor (EGFR) activation by radiation leads to increased cell
proliferation and acts as a radioresistance mechanism. Neoadjuvant chemoradiation is the …

Radiotherapy has a longstanding and well-defined role in the treatment of resectable rectal
cancer to reduce the historically high risk of local recurrence. In more advanced borderline …